Clinical Trials
2 trialsNCT04137900 2024-02-05
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
TopAlliance Biosciences
Phase 1 Unknown
NCT02836834 2019-10-22
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Unknown